Risk adapted therapy for newly diagnosed multiple myeloma delivered through local cytogenetic laboratories in a National Clinical Trial: UKMRA RADAR study

Ähnliche Einträge

• Challenges in designing and running smouldering myeloma interventional clinical trials
  von: Catherine Lecat, et al.
  Veröffentlicht: (2024)
• Outcomes of melphalan 140 mg/m2 followed by autologous stem cell transplantation in multiple myeloma patients with co‐morbidities: Single‐centre experience
  von: Dario Melotti, et al.
  Veröffentlicht: (2024)
• Real‐world characteristics and outcomes of patients with multiple myeloma receiving second‐line treatment in England
  von: Sally Moore, et al.
  Veröffentlicht: (2024)
• Myeloid neoplasm post cytotoxic treatment in patients with multiple myeloma
  von: Ke Xu, et al.
  Veröffentlicht: (2024)
• Increased serum B‐cell maturation antigen levels evaluated with an Elecsys‐based serum B‐cell maturation antigen assay have a negative prognostic value in patients with newly diagnosed multiple myeloma
  von: Evangelos Terpos, et al.
  Veröffentlicht: (2024)